Tarsus Pharmaceuticals, Inc. Stock Analysis & AI Score
Tarsus Pharmaceuticals, Inc. (TARS) has an ST Score of 50.5 (C+), driven by its Profitability (A) and held back by its Financial Strength (D). Analysts rate it Buy with a $103.00 price target (+35.6% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Tarsus Pharmaceuticals, Inc. (TARS) has an ST Score of 50.5 (C+), driven by its Profitability (A) and held back by its Financial Strength (D). Analysts rate it Buy with a $103.00 price target (+35.6% upside).
- Strongest
- ProfitabilityA
- Weakest
- Financial StrengthD
All factor grades
- ProfitabilityA
- MomentumA
- ForecastB-
- ValuationC
- GrowthC-
- Financial StrengthD
- Piotroski3/9
Contact
TARS stock: frequently asked questions
What is TARS's ST Score?
Tarsus Pharmaceuticals, Inc. (TARS) has an ST Score of 50.5 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is TARS a buy, hold, or sell?
Analysts rate TARS a Buy, with a price target of $103.00 (+35.6% vs the current price). Our ST Score grades it C+ (50.5/100). The ST Score is a data-driven signal, not a recommendation.
What are TARS's factor grades?
Valuation C, Profitability A, Financial Strength D, Momentum A, Growth C-, Forecast B-.
What is TARS's valuation grade?
Tarsus Pharmaceuticals, Inc. (TARS) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is TARS's growth grade?
Tarsus Pharmaceuticals, Inc. (TARS) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is TARS's profitability grade?
Tarsus Pharmaceuticals, Inc. (TARS) earns a profitability grade of A, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is TARS's financial strength grade?
Tarsus Pharmaceuticals, Inc. (TARS) earns a financial strength grade of D, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for TARS?
The average analyst price target for Tarsus Pharmaceuticals, Inc. (TARS) is $103.00 from 10 analysts, which is +35.6% versus the recent price of $75.96.
What is TARS's Piotroski score?
Tarsus Pharmaceuticals, Inc. (TARS) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.